公开(公告)号：US20170342418A1

公开(公告)日：2017-11-30

申请号：US15661346

申请日：2017-07-27

申请人： Shi-Lung LIN ,  Donald CHANG ,  David TS WU

发明人： Shi-Lung LIN ,  Donald CHANG ,  David TS WU

IPC分类号： C12N15/113 ,  C12P19/34 ,  C12N15/11 ,  C12N15/70

CPC分类号： C12N15/1135 ,  C12N15/111 ,  C12N15/113 ,  C12N15/70 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/30 ,  C12N2330/50 ,  C12N2330/51 ,  C12P19/34

摘要： This invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like RNA (shRNA) compositions, such as microRNA precursors (pre-miRNA) and short interfering RNAs (siRNA), which are useful for treating human ageing related diseases, such as, but not limited, Alzheimer's diseases, Parkinson's diseases, osteoporosis, diabetes, and cancers. The novelty of the present invention is to create an artificially enhanced adaptation environment for prokaryotic cells to adopt eukaryotic pol-2 and/or pol-2-like promoters for transcribing desired ncRNAs and/or their precursors without going through error-prone prokaryotic promoters, so as to improve the productive efficiency and reading fidelity of the shRNA transcription in the prokaryotic cells. The resulting shRNAs, preferably pre-miRNAs and siRNAs, are useful for developing therapeutic drugs against human degenerative diseases, particularly through a mechanism to induce CD34-positive stem cell expansion and/or regeneration.

公开(公告)号：US20140141470A1

公开(公告)日：2014-05-22

申请号：US14142512

申请日：2013-12-27

申请人： Shi-Lung LIN ,  Donald CHANG ,  David TS WU

发明人： Shi-Lung LIN ,  Donald CHANG ,  David TS WU

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  C12N15/111 ,  C12N2310/141 ,  C12N2330/50 ,  C12N2330/51

摘要： This invention generally relates to a composition for developing novel anti-cancer drugs and/or vaccines and producing microRNA precursor (pre-miRNA) and/or its shRNA homologues/mimics/derivatives, and a method thereof. The present invention also relates to a use of a composition in producing novel prokaryote-produced microRNA precursor (pro-miRNA) capable of being delivered into human cells and processed by the cells into microRNA-like effectors to elicit specific silencing effects on certain targeted oncogenes, subsequently leading to a therapeutic result of tumor suppression and cancer therapy. Specifically, the method of the present invention includes inducing an expression of the pre-miRNA/pro-miRNAs, particularly human pre-miR-302, in prokaryotes through pol-2 or pol-2-like RNA promoter. Most importantly, the composition of the present invention is further a novel pre-miRNA-based drug that is capable of reprogramming the malignant properties of high-grade human liver cancers into a low-grade benign or even relatively normal stage—a mechanism called “Cancer Reversion”.

摘要翻译： 本发明一般涉及用于开发新的抗癌药物和/或疫苗并产生微小RNA前体（pre-miRNA）和/或其shRNA同源物/模拟物/衍生物的组合物及其方法。 本发明还涉及一种组合物在生产新型原核生产的微小RNA前体（pro-miRNA）中的用途，其能够被递送到人类细胞中并被细胞加工成微小RNA样效应物以引发对某些靶向癌基因的特异性沉默效应 ，随后导致肿瘤抑制和癌症治疗的治疗结果。 具体地说，本发明的方法包括通过pol-2或pol-2样RNA启动子在原核生物中诱导前miRNA /前miRNAs，特别是人pre-miR-302的表达。 最重要的是，本发明的组合物还是一种新的基于前体miRNA的药物，其能够将高级别人类肝癌的恶性特征重新编程成低级良性或甚至相对正常的阶段 - 称为“ 癌症逆转“。

公开(公告)号：US20160264974A1

公开(公告)日：2016-09-15

申请号：US15167226

申请日：2016-05-27

申请人： Shi-Lung LIN ,  Donald CHANG ,  David TS WU

发明人： Shi-Lung LIN ,  Donald CHANG ,  David TS WU

IPC分类号： C12N15/113 ,  C12P19/34 ,  C12N15/70

CPC分类号： C12N15/1135 ,  C12N15/111 ,  C12N15/113 ,  C12N15/70 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/30 ,  C12N2330/50 ,  C12N2330/51 ,  C12P19/34

摘要： This invention generally relates to a composition and its production method useful for developing drugs/vaccines and/or therapies against a variety of degenerative diseases in humans. Particularly, the present invention teaches the essential steps of production and purification processes necessary for producing small hairpin-like RNA (shRNA) compositions, such as microRNA precursors (pre-miRNA) and short interfering RNAs (siRNA), which are useful for treating human ageing related diseases, such as, but not limited, Alzheimer's diseases, Parkinson's diseases, osteoporosis, diabetes, and cancers. The novelty of the present invention is to create an artificially enhanced adaptation environment for prokaryotic cells to adopt eukaryotic pol-2 and/or pol-2-like promoters for transcribing desired ncRNAs and/or their precursors without going through error-prone prokaryotic promoters, so as to improve the productive efficiency and reading fidelity of the shRNA transcription in the prokaryotic cells. The resulting shRNAs, preferably pre-miRNAs and siRNAs, are useful for developing therapeutic drugs against human degenerative diseases, particularly through a mechanism to induce CD34-positive stem cell expansion and/or regeneration.

摘要翻译： 本发明一般涉及用于开发针对人类各种退行性疾病的药物/疫苗和/或疗法的组合物及其制备方法。 特别地，本发明教导了用于生产小发夹样RNA（shRNA）组合物，例如可用于治疗人类的微小RNA前体（pre-miRNA）和短干扰RNA（siRNA））所需的生产和纯化过程的基本步骤 衰老相关疾病，例如但不限于阿尔茨海默病，帕金森病，骨质疏松症，糖尿病和癌症。 本发明的新颖之处在于为原核细胞产生人造增强的适应环境，以采用真核的pol-2和/或pol-2样启动子来转录所需的ncRNA和/或其前体而不经历易错的原核启动子， 从而提高原核细胞中shRNA转录的生产效率和阅读保真度。 产生的shRNA，优选pre-miRNAs和siRNAs可用于开发针对人退行性疾病的治疗药物，特别是通过诱导CD34阳性干细胞扩增和/或再生的机制。

公开(公告)号：US20160220525A1

公开(公告)日：2016-08-04

申请号：US15074321

申请日：2016-03-18

申请人： Shi-Lung LIN ,  Samantha CHANG-LIN ,  Yi-Wen LIN ,  Donald CHANG

发明人： Shi-Lung LIN ,  Samantha CHANG-LIN ,  Yi-Wen LIN ,  Donald CHANG

IPC分类号： A61K31/221 ,  A61K9/08 ,  A61K31/7024 ,  A61K9/00

CPC分类号： A61K31/221 ,  A61K9/0053 ,  A61K9/08 ,  A61K31/7012 ,  A61K31/7024 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/50 ,  C12N2330/51

摘要： This invention is related to a novel sugar-like chemical composition and its use for diabetes therapy. Particularly, the present invention teaches the use of monosaccharide-like glycylated sugar alcohol compounds to block or reduce sugar absorption in diabetes patients, so as to prevent the risk of hyperglycemia symptoms. Glycylation of sugar alcohols is a totally novel reaction that has never been reported before. Therefore, the novelty of the present invention is that for the first time glycylated sugar alcohols not only was found but also was found to be useful for treating Diabetes mellitus. In addition, the present invention teaches a method for producing these glycylated sugar alcohols. In sum, the present invention includes not only a kind of novel sugar-like chemical compositions and its use for treating diabetes but also a state-of-the-art protocol and methodology for producing such a novel composition via glycylation of sugars and sugar alcohols.

摘要翻译： 本发明涉及新型糖类化学组合物及其用于糖尿病治疗的用途。 特别地，本发明教导了使用单糖样的糖化糖醇化合物来阻止或减少糖尿病患者的糖吸收，以防止高血糖症状的风险。 糖醇的糖基化是一种完全新颖的反应，从未在之前报道过。 因此，本发明的新颖性不仅首次发现了糖化糖醇，而且被发现可用于治疗糖尿病。 此外，本发明教导了一种制备这些糖基化糖醇的方法。 总之，本发明不仅包括一种新型的糖类化学组合物及其用于治疗糖尿病的用途，而且还包括通过糖和糖醇的糖基化制备这种新型组合物的最新方案和方法 。

公开(公告)号：US20190085335A1

公开(公告)日：2019-03-21

申请号：US16135723

申请日：2018-09-19

申请人： Shi-Lung LIN ,  Samantha CHANG-LIN ,  Donald CHANG

发明人： Shi-Lung LIN ,  Samantha CHANG-LIN ,  Donald CHANG

IPC分类号： C12N15/113 ,  C12N15/70 ,  C12N15/11 ,  C12P19/34

摘要： This invention generally relates to a composition and its method of use for inducing adult stem cell (ASC) expansion and/or derivation in vitro, using miR-302-like pre-miRNAs, shRNAs and/or siRNAs, all of which contain a shared sequence of 5′-UAAGUGCUUC CAUGUUU-3′ (SEQ ID NO: 7) in the 5′-end, and further in conjunction with the use of some wound-healing-related defined factors, including but not limited to basic fibroblast growth factor (bFGF)/fibroblast growth factor 2 (FGF-2), leukemia inhibitory factor (LIF), insulin-like growth factor (IGF), Epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), tumor necrosis factor (TNF), stem cell factor (SCF), homeobox proteins (HOX), Notch, GSK, Wnt/beta-Catenin signals, interleukins, and/or bone morphogenetic proteins (BMPs). The principle of the present invention is related to a novel mechanism of inducible symmetric ASC division recently found in a skin wound healing model in vivo. The resulting amplified ASCs are useful for treating a variety of human aging- and cell dysfunction-associated disorders, including but not limited to Alzheimer's disease, Parkinson's disease, motor neuron disease, stroke, diabetes, osteoporosis, myocardial infraction, hemophilia, anemia, AIDS, leukemia, lymphoma and many kinds of cancers as well as aging.